secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001023024-24-000088
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma completes Alimera acquisition; expects high single-digit to low double-digit EPS accretion in 2025
--------------------------------------------------------------------------------

- Acquired Alimera for $5.50/share plus CVR up to $0.50/share based on 2026-27 net revenue targets; repaid $72.5M Alimera debt.
- Alimera adds ~$105M in pro forma 2024 revenue; Rare Disease segment to become ~45% of pro forma revenues.
- New capital: $316.25M 2.25% convertible notes due 2029; new $325M term loan; interest expense reduced ~$39M annually.
- Expects high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS; substantially accretive thereafter; $35-38M adj. EBITDA.
- Cortrophin Gel record new patient starts in Aug; ophthalmology team >3,600 physicians; 14 generic products launched YTD; maintains standalone 2024 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/0001023024-24-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/ani-20240916.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer